• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein

    Thumbnail
    View/ Open
    s41419-019-1892-7.pdf (1.766Mb)

    Show full item record
    
    Author
    Byun, Jung S.; Park, Samson; Yi, Dae Ik; Shin, Jee-Hye; Hernandez, Sara Gil; Hewitt, Stephen M.; Nicklaus, Marc C.; Peach, Megan L.; Guasch, Laura; Tang, Binwu; Wakefield, Lalage M.; Yan, Tingfen; Caban, Ambar; Alana, Jones; Kabbout, Mohamed; Vohra, Nasreen; Nápoles, Anna María; Singhal, Sandeep; Yancey, Ryan; Siervi, Adriana De; Gardner, Kevin
    Abstract
    The C-terminal binding protein (CtBP) is an NADH-dependent dimeric family of nuclear proteins that scaffold interactions between transcriptional regulators and chromatin-modifying complexes. Its association with poor survival in several cancers implicates CtBP as a promising target for pharmacological intervention. We employed computer-assisted drug design to search for CtBP inhibitors, using quantitative structure-activity relationship (QSAR) modeling and docking. Functional screening of these drugs identified 4 compounds with low toxicity and high water solubility. Micro molar concentrations of these CtBP inhibitors produces significant de-repression of epigenetically silenced pro-epithelial genes, preferentially in the triple-negative breast cancer cell line MDA-MB-231. This epigenetic reprogramming occurs through eviction of CtBP from gene promoters; disrupted recruitment of chromatin-modifying protein complexes containing LSD1, and HDAC1; and re-wiring of activating histone marks at targeted genes. In functional assays, CtBP inhibition disrupts CtBP dimerization, decreases cell migration, abolishes cellular invasion, and improves DNA repair. Combinatorial use of CtBP inhibitors with the LSD1 inhibitor pargyline has synergistic influence. Finally, integrated correlation of gene expression in breast cancer patients with nuclear levels of CtBP1 and LSD1, reveals new potential therapeutic vulnerabilities. These findings implicate a broad role for this class of compounds in strategies for epigenetically targeted therapeutic intervention.
    URI
    http://hdl.handle.net/10342/8073
    Date
    2019-08-08
    Citation:
    APA:
    Byun, Jung S., & Park, Samson, & Yi, Dae Ik, & Shin, Jee-Hye, & Hernandez, Sara Gil, & Hewitt, Stephen M., & Nicklaus, Marc C., & Peach, Megan L., & Guasch, Laura, & Tang, Binwu, & Wakefield, Lalage M., & Yan, Tingfen, & Caban, Ambar, & Alana, Jones, & Kabbout, Mohamed, & Vohra, Nasreen, & Nápoles, Anna María, & Singhal, Sandeep, & Yancey, Ryan, & Siervi, Adriana De, & Gardner, Kevin. (August 2019). Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein. Cell Death & Disease, (689. Retrieved from http://hdl.handle.net/10342/8073

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Byun, Jung S., and Park, Samson, and Yi, Dae Ik, and Shin, Jee-Hye, and Hernandez, Sara Gil, and Hewitt, Stephen M., and Nicklaus, Marc C., and Peach, Megan L., and Guasch, Laura, and Tang, Binwu, and Wakefield, Lalage M., and Yan, Tingfen, and Caban, Ambar, and Alana, Jones, and Kabbout, Mohamed, and Vohra, Nasreen, and Nápoles, Anna María, and Singhal, Sandeep, and Yancey, Ryan, and Siervi, Adriana De, and Gardner, Kevin. "Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein". Cell Death & Disease. . (689.), August 2019. July 06, 2022. http://hdl.handle.net/10342/8073.
    Chicago:
    Byun, Jung S. and Park, Samson and Yi, Dae Ik and Shin, Jee-Hye and Hernandez, Sara Gil and Hewitt, Stephen M. and Nicklaus, Marc C. and Peach, Megan L. and Guasch, Laura and Tang, Binwu and Wakefield, Lalage M. and Yan, Tingfen and Caban, Ambar and Alana, Jones and Kabbout, Mohamed and Vohra, Nasreen and Nápoles, Anna María and Singhal, Sandeep and Yancey, Ryan and Siervi, Adriana De and Gardner, Kevin, "Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein," Cell Death & Disease 10, no. (August 2019), http://hdl.handle.net/10342/8073 (accessed July 06, 2022).
    AMA:
    Byun, Jung S., Park, Samson, Yi, Dae Ik, Shin, Jee-Hye, Hernandez, Sara Gil, Hewitt, Stephen M., Nicklaus, Marc C., Peach, Megan L., Guasch, Laura, Tang, Binwu, Wakefield, Lalage M., Yan, Tingfen, Caban, Ambar, Alana, Jones, Kabbout, Mohamed, Vohra, Nasreen, Nápoles, Anna María, Singhal, Sandeep, Yancey, Ryan, Siervi, Adriana De, Gardner, Kevin. Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein. Cell Death & Disease. August 2019; 10() 689. http://hdl.handle.net/10342/8073. Accessed July 06, 2022.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback